- Home
- UCL vs BLRX Comparison
UCL vs BLRX Comparison
Compare UCL & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UCL
- BLRX
- Stock Information
- Founded
- UCL 2014
- BLRX 2003
- Country
- UCL Hong Kong
- BLRX Israel
- Employees
- UCL N/A
- BLRX N/A
- Industry
- UCL Telecommunications Equipment
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- UCL Consumer Discretionary
- BLRX Health Care
- Exchange
- UCL Nasdaq
- BLRX Nasdaq
- Market Cap
- UCL 48.4M
- BLRX 54.1M
- IPO Year
- UCL 2020
- BLRX 2011
- Fundamental
- Price
- UCL $1.19
- BLRX $0.46
- Analyst Decision
- UCL
- BLRX Strong Buy
- Analyst Count
- UCL 0
- BLRX 2
- Target Price
- UCL N/A
- BLRX $11.50
- AVG Volume (30 Days)
- UCL 24.5K
- BLRX 314.6K
- Earning Date
- UCL 11-13-2024
- BLRX 11-18-2024
- Dividend Yield
- UCL N/A
- BLRX N/A
- EPS Growth
- UCL N/A
- BLRX N/A
- EPS
- UCL 0.12
- BLRX N/A
- Revenue
- UCL $86,076,000.00
- BLRX $17,048,000.00
- Revenue This Year
- UCL $11.23
- BLRX N/A
- Revenue Next Year
- UCL $27.52
- BLRX N/A
- P/E Ratio
- UCL $10.35
- BLRX N/A
- Revenue Growth
- UCL 10.63
- BLRX N/A
- 52 Week Low
- UCL $1.16
- BLRX $0.43
- 52 Week High
- UCL $2.96
- BLRX $1.93
- Technical
- Relative Strength Index (RSI)
- UCL 37.46
- BLRX 26.70
- Support Level
- UCL $1.16
- BLRX $0.43
- Resistance Level
- UCL $1.29
- BLRX $0.56
- Average True Range (ATR)
- UCL 0.07
- BLRX 0.05
- MACD
- UCL -0.01
- BLRX -0.01
- Stochastic Oscillator
- UCL 11.11
- BLRX 12.42
About UCL uCloudlink Group Inc.
Ucloudlink Group Inc provides mobile data connectivity and portable WiFi services. The business operates under uCloudlink 1.0, which focuses on cross-border travelers that need mobile data connectivity services across different countries. Under uCloudlink 2.0, provides mobile data connectivity services to local users across different MNOs in a single country. It generates revenue from the provision of data connectivity services, and the sales of terminals and sales of data related products.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.